|
|
Article: Celldex Starts Phase II/III Trial Of Peptide Vaccine In Brain Cancer.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Celldex Therapeutics Inc. began a Phase II/III trial of its peptide vaccine CDX-110 in patients with newly diagnosed glioblastoma multiforme.
Company officials are encouraged by earlier Phase II data on disease progression and survival, and on updated data from that study to be presented at the upcoming American Society of Clinical Oncology meeting. CDX-110 is an immunotherapy that targets epidermal growth factor receptor variant III, a functional variant of EGFR.
The Phase II/III randomized study will enroll patients whose tumors express that mutation. It will compare the vaccine plus the standard of care, temozolomide (Temodar, ...